PRRT has been successfully used to treat NETs due to their high expression levels of SSTR2 [8,9,10], but PRRT may also be effective for other cancers, such as primary brain tumours [5], paragangliomas [11,12,13,14], or thyroid cancer [15,16,17,18]. Here, SSTR2 is linked to brain neoplasm.